ATF2 Rabbit anti-Human, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA527129
PA5-27129 targets ATF2 in IHC (P) applications and shows reactivity with Human samples. The PA5-27129 immunogen is a synthetic peptide corresponding to a region within amino acids 442 and 505 of ATF2. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial. For short-term storage (1-2 weeks), product can be stored at 4°C. For long-term storage, aliquot and store product at -20° C or below, avioiding multiple freeze-thaw cycles.This gene encodes a transcription factor that is a member of the leucine zipper family of DNA binding proteins. This protein binds to the cAMP-responsive element (CRE), an octameric palindrome. The protein forms a homodimer or heterodimer with c-Jun and stimulates CRE-dependent transcription. The protein is also a histone acetyltransferase (HAT) that specifically acetylates histones H2B and H4 in vitro; thus it may represent a class of sequence-specific factors that activate transcription by direct effects on chromatin components. Additional transcript variants have been identified but their biological validity has not been determined.
|Synthetic peptide corresponding to a region within amino acids 442 and 505 of ATF2|
|Antigen affinity chromatography|
|PBS with 1% BSA, 20% glycerol and 0.01% thimerosal; pH 7|
|CRE-BP1, CREB2, HB16, TREB7, CREB-2, activating transcription factor 2 splice variant ATF2-var2, cAMP response element-binding protein CRE-BP1, cAMP responsive element binding protein 2, formerly, cAMP-dependent transcription factor ATF-2, cAMP-responsive element-binding protein 2, cyclic|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok